Overview
EXO Biologics focuses on extracellular vesicles (EVs) and exosomes as therapeutic messengers, positioning them as safer, more consistent, and more stable alternatives to cell-based approaches. The company operates a CDMO platform targeting rare inflammatory diseases with a focus on drug loading, delivery, and GMP manufacturing of exosomes derived from cultured human umbilical cord mesenchymal stromal cells.
Something wrong or missing? Send an update. Fixed within 24 hours.